Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Egalet Corp ($EGLT) reported that it has received four new U.S. and international patents for Egalet's proprietary Guardian™ Technology. The US patent is number 9,549,899 covering ARYMO™ ER (morphine sulfate) extended-release tablets for oral use only. It is  the second U.S. patent covering ARYMO ER. The patent offers protection through 2033 and is listed in the Orange Book. It has received a patent in Canada as well which is related to  Guardian Technology's immediate-release system designed to slow the release of the active pharmaceutical ingredient in the presence of alcohol. 
The European patent number 2393487 has been issued to Egalet and offers protection of products developed using Guardian Technology. The third patent awarded in Australia is patent number 2015200243. Both the European and Australian patents offer protection through 2030.

Mednax Inc. ($MD) announced that it has acquired the Henderson, NV pediatric ophthalmology practice of Dr. Bruce Snyder. The companies did not disclose the financial terms of the agreement. Bruce E. Snyder, M.D., PLLC. employs one physician and three full-time non-clinical associates and provides ophthalmology services to pediatric and adult patients. It specializes in retinopathy of prematurity (ROP) screening and visual care consultative services. The practice services 11 hospitals and three surgery centers throughout the Las Vegas area.
This acquisition adds to the services MEDNAX provides in Nevada which include anesthesiology, neonatology, newborn hearing screen and pediatric intensive care. The company stock price has gained 7 percent this year so far.


Stemline Therapeutics ($STML) reported that it has completed its enrollment target for the third and last stage in its Phase 2 clinical trial assessing Breakthrough Therapy-tagged SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm. The study has enrolled a total of 47 BPDCN patients, 32 first-line and 15 relapsed/refractory. The company plans to provide a clinical update on patients participating in Stages 1 and 2 at a medical conference around mid-year and will release top-line data from Stage 3 in H2. 

Mylan NV ($MYL) announced that it has recalled about 81,000 EpiPen devices in countries outside the United States, following two reports of the life-saving allergy shot failing to work in emergencies. The recall affects devices distributed in Australia, New Zealand, Europe and Japan only, according to the company. The company said it is working with the regulatory authorities, where appropriate, to inform them about the recall.

ChemoCentryx ($CCXI) receives  an Orphan Drug designation from the FDA for its avaopan, designed for the treatment of C3 glomerulopathy (C3G). Small molecule avacopan arrests the kidney damage associated with C3G by inhibiting the complement C5a receptor which plays a key role in the inflammatory process. An efficacy study will be initiated next quarter.

Sunesis Pharmaceuticals ($SNSS) announced submitting its  responses to the European Medicines Agency's Day 180 List of Outstanding Issues generated by the Committee for Medicinal Products for Human Use (CHMP) regarding its marketing application seeking approval of vosaroxin for the treatment of relapsed/refractory acute myeloid leukemia (AML). The responses and clinical data will be review by the advisory group's Oncology Division next month.


Hologic ($HOLX) reported completion of its acquisition of Cynosure Inc. The deal has been done at $66 per share in cash. The collaboration is expected to help Hologic in cracking medical aesthetics market. The tender offer by a subsidiary of Hologic for all the outstanding shares of Cynosure Class A Common Stock expired as scheduled at midnight ET on March 21, 2017.  A total of 17,047,830 shares of Cynosure Class A Common Stock, representing approximately 70.6% of Cynosure's outstanding shares, were validly tendered into and not validly withdrawn from the tender offer. 


ARCA Biopharma ($ABIO) announced its net loss for the year 2016 at $16.4 million, or $1.81 per share, for 2016 compared to $11.4 million, or $1.82 per share, for 2015. Its total operating expenses for the year were $16.6 million compared to $11.5 million in 2015.  ARCA closed the year with $23.5 million in cash, cash equivalents and marketable securities. The company believes that the balance would sufficient to fund its operations, at its projected cost structure, through the end of 2017.

Imprimis Pharmaceuticals ($IMMY) reported a loss of $6.1 million in its fourth quarter. On a per-share basis, the San Diego-based company suffered a loss of $0.44. Its revenue for the quarter stood at $5.8 million. For the entire year, Imprimis reported its loss at $19.1 million, or $1.50 per share. Revenue was reported as $19.9 million.

Price Target
Impact on Share Price
Centene Corp (CNC)
Buy -> Neutral

Noble Financial
Heat Biologics (HTBX)

Icon Plc (ICLR)
JPMorgan Chase & Co.
Novartis AG (NVS)

Lowers Target
Pacira Pharmaceuticals (PCRX)
$59.00 -> $54.00
PAREXEL International (PRXL)
Lowers Target
Ultragenyx Pharmaceutical (RARE)
$88.00 -> $80.00
Royal Bank of Canada
Lowers Target
Valeant Pharmaceuticals Intl (VRX)


Gainers (% price change) Last Trade Change Mkt Cap
Idera Pharmaceuticals Inc IDRA 2.49 +0.40 (19.14%) 347.94M
China Cord Blood Corp CO 6.06 +0.43 (7.64%) 439.91M
Antares Pharma Inc ATRS 2.80 +0.15 (5.66%) 408.47M
Cytokinetics, Inc. CYTK 12.80 +0.60 (4.92%) 521.32M
Nektar Therapeutics NKTR 22.89 +1.06 (4.86%) 3.52B
Losers (% price change)
Allscripts Healthcare MDRX 11.66 -0.64 (-5.20%) 2.10B
PDL BioPharma Inc PDLI 2.05 -0.11 (-5.09%) 336.28M
Codexis, Inc. CDXS 4.40 -0.20 (-4.35%) 177.51M
Fluidigm Corporation FLDM 5.25 -0.23 (-4.20%) 160.67M
Keryx Biopharmaceuticals KERX 5.45 -0.23 (-4.05%) 529.88M
Most Actives (dollar volume)
Johnson & Johnson JNJ 126.26 -0.99 (-0.78%) 340.09B
Pfizer Inc. PFE 34.47 +0.22 (0.64%) 204.50B
Amgen, Inc. AMGN 167.45 +0.60 (0.36%) 121.58B
Merck & Co., Inc. MRK 63.50 -0.41 (-0.64%) 173.80B
Bristol-Myers Squibb Co BMY 56.36 +0.65 (1.17%) 94.27B